Epix appoints marketing VP
MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in
MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the companys MS-325 MRI contrast agent, which is in phase II clinical trials for peripheral vascular disease, coronary artery disease, and breast cancer (SCAN 1/14/98). Mayer joins Cambridge, MA-based Epix from a position as worldwide marketing manager at pharmaceutical firm Chiron Diagnostics. He has also been employed by Abbott Diagnostics.